Recent advances in targeting protein kinases and pseudokinases in cancer biology

Kinases still remain the most favorable members of the druggable genome, and there are an increasing number of kinase inhibitors approved by the FDA to treat a variety of cancers. Here, we summarize recent developments in targeting kinases and pseudokinases with some examples. Targeting the cell cyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Riegel, Kristina, Vijayarangakannan, Parthiban, Kechagioglou, Petros, Bogucka, Katarzyna, Rajalingam, Krishnaraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354965/
https://www.ncbi.nlm.nih.gov/pubmed/35938171
http://dx.doi.org/10.3389/fcell.2022.942500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354965/
https://www.ncbi.nlm.nih.gov/pubmed/35938171
http://dx.doi.org/10.3389/fcell.2022.942500

Ejemplares similares